• Humacyte’s Phase 3 V012 interim results showed its bioengineered vessel outperformed fistulas for dialysis access in women, meeting the primary endpoint.
• Results presented October 22, 2026, at ASN Kidney Week showed faster usable access and less catheter dependence.
• Safety was comparable to fistulas, with fewer dialysis access infections observed among vessel recipients.
• Enrollment stopped because the trial met its primary endpoint.
• The findings support a planned FDA application this quarter to expand Symvess’ label to include dialysis access.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610230800PRIMZONEFULLFEED9851781) on October 23, 2026, and is solely responsible for the information contained therein.